CONMED (US:CNMD)2025-07-30 20:30Financial Performance - Q2 2025 - Worldwide revenue reached $342.3 million, representing a 2.9% increase in constant currency compared to the prior year period[22] - Orthopedic surgery revenue was $140.7 million, with a constant currency growth of 0.8%[22] - General surgery revenue amounted to $201.6 million, showing a constant currency growth of 4.4%[22] - GAAP EPS was $0.69, a decrease of 28.1% year-over-year, while adjusted EPS was $1.15, an increase of 17.3%[22] - Single-use products accounted for $297.8 million in revenue, while capital products generated $44.5 million[24] - Single-use products represent 87% of the total revenue[24] Financial Performance - June 2025 YTD - Worldwide revenue totaled $663.6 million, a 3.3% increase in constant currency[28] - Orthopedic surgery revenue was $279.0 million, with a constant currency growth of 2.3%[28] - General surgery revenue reached $384.6 million, showing a constant currency growth of 4.1%[28] - GAAP EPS was $0.88, a decrease of 44.7% year-over-year, while adjusted EPS was $2.09, an increase of 17.4%[28] - Single-use products accounted for $574.1 million in revenue, while capital products generated $89.5 million[30] - Single-use products represent 87% of the total revenue[30] Updated Financial Guidance for 2025 - The company updated its revenue guidance to a range of $1.356 billion to $1.378 billion, with immaterial currency impact[32] - Adjusted diluted EPS is expected to be between $4.59 and $4.74, with an estimated foreign currency impact of $(0.10)[32] - The estimated tariff impact is $(0.09), resulting in a total adjusted diluted EPS of $4.40 to $4.55[32]